AI Engines For more Details: Perplexity Kagi Labs You
Diuretic Effect: Benzamil hydrochloride belongs to a class of medications known as potassium-sparing diuretics. It works by blocking the activity of epithelial sodium channels (ENaC) in the kidneys, which reduces the reabsorption of sodium ions and water from the urine back into the bloodstream. This increases the amount of sodium and water excreted in the urine, leading to diuresis (increased urine production) and decreased fluid retention in the body.
Blood Pressure Reduction: By promoting diuresis and reducing fluid volume in the bloodstream, benzamil hydrochloride helps lower blood pressure. It is particularly useful in cases where high blood pressure is due to excess fluid retention, such as in congestive heart failure.
Congestive Heart Failure: Benzamil hydrochloride is often used as adjunctive therapy in the management of congestive heart failure (CHF). By reducing fluid overload in the body, it helps alleviate symptoms such as shortness of breath, swelling (edema), and fatigue associated with CHF.
Edema: Edema is a condition characterized by abnormal accumulation of fluid in the body's tissues, leading to swelling and discomfort. Benzamil hydrochloride can help reduce edema by increasing urinary sodium and water excretion, thereby reducing fluid buildup in the tissues.
Potassium-Sparing: Unlike some other diuretics that can cause potassium loss (hypokalemia), benzamil hydrochloride is potassium-sparing, meaning it does not typically cause significant potassium excretion in the urine. This is advantageous, especially in patients who are at risk of low potassium levels or who are already taking medications that can deplete potassium.
Electrolyte Balance: While benzamil hydrochloride primarily affects sodium and water excretion, it may also impact the excretion of other electrolytes such as potassium and hydrogen ions. Close monitoring of electrolyte levels, particularly potassium, is necessary during treatment with benzamil hydrochloride to prevent imbalances.
Heart and Kidney Protection: By reducing fluid overload and blood pressure, benzamil hydrochloride may help protect the heart and kidneys from damage associated with hypertension and fluid retention. It can help improve cardiac function and reduce the risk of complications such as heart attack, stroke, and kidney failure.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.6 | 0.8 | -0.33 |
| ADHD | 3.8 | 0.6 | 5.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 1.3 | 1.62 |
| Allergies | 4.3 | 1.5 | 1.87 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 4.7 | 6.1 | -0.3 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.5 | 3.6 |
| Ankylosing spondylitis | 3.1 | 1.2 | 1.58 |
| Anorexia Nervosa | 1.6 | 2.6 | -0.63 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 3.7 | 1.8 | 1.06 |
| Atherosclerosis | 1.6 | 1.8 | -0.13 |
| Atrial fibrillation | 3.4 | 2.4 | 0.42 |
| Autism | 7.7 | 7 | 0.1 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.6 | 1.9 | -2.17 |
| Carcinoma | 3.8 | 2.6 | 0.46 |
| Celiac Disease | 2.2 | 3.2 | -0.45 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 4 | 5.4 | -0.35 |
| Chronic Kidney Disease | 3.9 | 2.5 | 0.56 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.4 | -0.17 |
| Chronic Urticaria (Hives) | 1.6 | 0.3 | 4.33 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.3 | 1.6 | 1.06 |
| Colorectal Cancer | 6 | 2.4 | 1.5 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 2.5 | 2.6 | -0.04 |
| COVID-19 | 5.8 | 7.3 | -0.26 |
| Crohn's Disease | 7.2 | 4.2 | 0.71 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.3 | -0.63 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.3 | 1.4 | 0.64 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 8.2 | 7.6 | 0.08 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.2 | 0.67 |
| Endometriosis | 3.1 | 1.9 | 0.63 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.6 | 1.1 | 1.36 |
| erectile dysfunction | 1.7 | 0.3 | 4.67 |
| Fibromyalgia | 2.2 | 1.6 | 0.38 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 3.5 | 0.37 |
| gallstone disease (gsd) | 3.6 | 0.8 | 3.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.5 | 1.2 |
| Generalized anxiety disorder | 2.4 | 2.2 | 0.09 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.1 | 0.8 | 0.38 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 0.7 | 0.29 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.2 | 1.3 | 1.46 |
| Heart Failure | 3.2 | 1.8 | 0.78 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1 | 1.1 | -0.1 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.7 | 4.1 | -0.11 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.3 | 3 | -1.31 |
| Inflammatory Bowel Disease | 6 | 5.3 | 0.13 |
| Insomnia | 1.9 | 2.1 | -0.11 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 5.7 | 4.6 | 0.24 |
| ischemic stroke | 2.5 | 1.7 | 0.47 |
| Liver Cirrhosis | 6.4 | 3.5 | 0.83 |
| Long COVID | 6 | 4.9 | 0.22 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.1 | 1 | 0.1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 1.7 | -0.55 |
| ME/CFS without IBS | 1.1 | 1.6 | -0.45 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.2 | 0.5 | 1.4 |
| Metabolic Syndrome | 6.4 | 6.6 | -0.03 |
| Mood Disorders | 7.4 | 6.4 | 0.16 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 4.6 | 4.4 | 0.05 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.7 | -2.7 | |
| Neuropathy (all types) | 0.4 | 2.1 | -4.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.2 | 3.3 | 0.27 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 8.3 | 6 | 0.38 |
| obsessive-compulsive disorder | 4 | 3.5 | 0.14 |
| Osteoarthritis | 2.3 | 1.2 | 0.92 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 5.2 | 4.9 | 0.06 |
| Polycystic ovary syndrome | 5.3 | 2.7 | 0.96 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1 | 0.2 |
| Primary sclerosing cholangitis | 1.8 | 2.4 | -0.33 |
| Psoriasis | 2.3 | 2.3 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.6 | 4 | 0.4 |
| Rosacea | 1.1 | 1 | 0.1 |
| Schizophrenia | 4.5 | 2.8 | 0.61 |
| scoliosis | 0.5 | 0.6 | -0.2 |
| Sjögren syndrome | 2.2 | 2.3 | -0.05 |
| Sleep Apnea | 1.6 | 1.6 | 0 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.3 | 4 |
| Stress / posttraumatic stress disorder | 2.5 | 2.1 | 0.19 |
| Systemic Lupus Erythematosus | 3.9 | 1.6 | 1.44 |
| Tic Disorder | 1.5 | 1.2 | 0.25 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.1 | 3.2 | 0.28 |
| Type 2 Diabetes | 7.8 | 5.6 | 0.39 |
| Ulcerative colitis | 4.5 | 5.3 | -0.18 |
| Unhealthy Ageing | 4.6 | 2.4 | 0.92 |
| Vitiligo | 1.8 | 1.5 | 0.2 |
